Is NEVPF or JEPI a better dividend investment in 2026?

NEVPF currently yields 7142.86% with a 5% 5-year dividend growth rate. JEPI yields 8.40% with 2.1% growth. The better choice depends on your goal: NEVPF offers higher current income.

What is the dividend yield difference between NEVPF and JEPI?

NEVPF has a forward dividend yield of 7142.86% ($2.00/share annually). JEPI yields 8.40% ($4.76/share annually). The yield gap is 7134.46 percentage points.

Home › Compare › NEVPF vs JEPI

NEVPF vs JEPI: Dividend Comparison 2026

NEVPF yields 7142.86% · JEPI yields 8.40%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NEVPF wins by $2020155342665731.25M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NEVPF

● Live price

7142.86%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2020155342665731.25M

Annual income

$1,966,011,161,323,515,200,000.00

Full NEVPF calculator →

JEPI

JPMorgan Equity Premium Income ETF

● Live price

8.40%

Share price

$56.68

Annual div

$4.76

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.0K

Annual income

$1,528.62

Full JEPI calculator →

Portfolio growth — NEVPF vs JEPI

📍 NEVPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NEVPF	JEPI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NEVPF + JEPI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NEVPF pays

JEPI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEVPF

Annual income on $10K today (after 15% tax)

$607,142.86/yr

After 10yr DRIP, annual income (after tax)

$1,671,109,487,124,987,800,000.00/yr

JEPI

Annual income on $10K today (after 15% tax)

$714.16/yr

After 10yr DRIP, annual income (after tax)

$1,299.33/yr

At 15% tax rate, NEVPF beats the other by $1,671,109,487,124,987,800,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEVPF + JEPI for your $10,000?

NEVPF: 50%JEPI: 50%

100% JEPI50/50100% NEVPF

Portfolio after 10yr

$1010077671332865.63M

Annual income

$983,005,580,661,757,600,000.00/yr

Blended yield

97.32%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEVPF buys

JEPI buys

No recent congressional trades found for NEVPF or JEPI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNEVPFJEPI

Forward yield	7142.86% ✓	8.40%
Annual dividend / share	$2.00	$4.76 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2020155342665731.25M ✓	$29.0K
Annual income after 10y	$1,966,011,161,323,515,200,000.00 ✓	$1,528.62
Total dividends collected	$2016528271361529.00M ✓	$11.7K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: NEVPF vs JEPI ($10,000, DRIP)

Year	NEVPF Portfolio	NEVPF Income/yr	JEPI Portfolio	JEPI Income/yr	Gap
1← crossover	$724,986	$714,285.71	$11,260	$840.19	+$713.7K → NEVPF
2	$49,172,645	$48,396,910.17	$12,641	$907.94	+$49.16M → NEVPF
3	$3,120,421,331	$3,067,806,600.72	$14,150	$978.20	+$3120.41M → NEVPF
4	$185,281,229,916	$181,942,379,091.82	$15,795	$1,050.85	+$185281.21M → NEVPF
5	$10,294,691,143,508	$10,096,440,227,497.77	$17,584	$1,125.74	+$10294691.13M → NEVPF
6	$535,299,070,050,255	$524,283,750,526,701.75	$19,526	$1,202.74	+$535299070.03M → NEVPF
7	$26,050,796,629,539,330	$25,478,026,624,585,550.00	$21,628	$1,281.69	+$26050796629.52M → NEVPF
8	$1,186,669,129,317,434,600	$1,158,794,776,923,827,700.00	$23,898	$1,362.43	+$1186669129317.41M → NEVPF
9	$50,602,038,637,584,920,000	$49,332,302,669,215,270,000.00	$26,347	$1,444.79	+$50602038637584.89M → NEVPF
10	$2,020,155,342,665,731,300,000	$1,966,011,161,323,515,200,000.00	$28,982	$1,528.62	+$2020155342665731.25M → NEVPF

NEVPF vs JEPI: Complete Analysis 2026

NEVPF — Stock

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Full NEVPF Calculator →

JEPI — ETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →

📬

Get this NEVPF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEVPF vs SCHD NEVPF vs O NEVPF vs KO NEVPF vs MAIN NEVPF vs JEPQ NEVPF vs XYLD NEVPF vs DIVO NEVPF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.